3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Squamous Cell Carcinoma of Head and Neck
10
Melanoma
8
Lung Neoplasms
8
Neoplasms
7
Carcinoma
6
Skin Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Squamous Cell
5
Carcinoma, Basal Cell
5
Adenocarcinoma
5
Mouth Neoplasms
4
Head and Neck Neoplasms
4
Colonic Neoplasms
4
Carcinoma, Renal Cell
4
Urinary Bladder Neoplasms
3
Sarcoma
3
Oropharyngeal Neoplasms
3
Laryngeal Neoplasms
3
Carcinoma, Merkel Cell
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma, Malignant
2
Hemangiosarcoma
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Adrenocortical Carcinoma
2
Interventions
Trastuzumab
5
Carboplatin
4
toripalimab
2
pertuzumab
2
pembrolizumab
2
Tretinoin
2
Paclitaxel
2
Immunotherapy
2
Drug Therapy
2
Doxorubicin
2
Docetaxel
2
Cytarabine
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
temsirolimus
1
talazoparib
1
tagraxofusp
1
sarilumab
1
sargramostim
1
pyrotinib
1
pexidartinib
1
pazopanib
1
patritumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pathologic Complete Response
×
cemiplimab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled